Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Pau-Charles

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Actas Dermo-Sifiliograficas|July 9, 2011
[Skin signs in child abuse]I Pau-Charles, E Darwich-Soliva, R Grimalt
Clinical and Experimental Dermatology|April 25, 2014
Acquired hypopigmented suprapubic maculesI Pau-Charles, A Vicente, C Jou, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2021
Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trialsD Thaçi, D Jullien, A Egeberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 30, 2019
Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE studyP C M van de Kerkhof, R Loewe, U Mrowietz, et al.
The British Journal of Dermatology|August 13, 2016
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm<sup>®</sup> - and placebo-controlled trial (BRIDGE)U Mrowietz, J C Szepietowski, R Loewe, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2014
Anti-MDA5 positive clinically amyopathic dermatomyositis presenting with severe cardiomyopathyI Pau-Charles, P J Moreno, K Ortiz-Ibáñez, et al.
The British Journal of Dermatology|June 21, 2019
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeksK Reich, R B Warren, L Iversen, et al.
The British Journal of Dermatology|February 5, 2021
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)D Thaci, S Piaserico, R B Warren, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2022
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2A P Fernandez, E Dauden, S Gerdes, et al.
Clinical and Experimental Dermatology|October 11, 2017
First-line treatment in lymphomatoid papulosis: a retrospective multicentre studyR Fernández-de-Misa, B Hernández-Machín, O Servitje, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Actas Dermo-Sifiliograficas|July 9, 2011
[Skin signs in child abuse]I Pau-Charles, E Darwich-Soliva, R Grimalt
Clinical and Experimental Dermatology|April 25, 2014
Acquired hypopigmented suprapubic maculesI Pau-Charles, A Vicente, C Jou, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2021
Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trialsD Thaçi, D Jullien, A Egeberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 30, 2019
Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE studyP C M van de Kerkhof, R Loewe, U Mrowietz, et al.
The British Journal of Dermatology|August 13, 2016
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm<sup>®</sup> - and placebo-controlled trial (BRIDGE)U Mrowietz, J C Szepietowski, R Loewe, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2014
Anti-MDA5 positive clinically amyopathic dermatomyositis presenting with severe cardiomyopathyI Pau-Charles, P J Moreno, K Ortiz-Ibáñez, et al.
The British Journal of Dermatology|June 21, 2019
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeksK Reich, R B Warren, L Iversen, et al.
The British Journal of Dermatology|February 5, 2021
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)D Thaci, S Piaserico, R B Warren, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2022
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2A P Fernandez, E Dauden, S Gerdes, et al.
Clinical and Experimental Dermatology|October 11, 2017
First-line treatment in lymphomatoid papulosis: a retrospective multicentre studyR Fernández-de-Misa, B Hernández-Machín, O Servitje, et al.
Pageof 1